Communiqués argenx SE

Actions

ARGX

NL0010832176

Recherche biotechnologique et médicale

PEA

Marché Fermé - Euronext Bruxelles Autres places de cotation 17:55:00 20/07/2026			Varia. 5j.	Varia. 1 janv.
753,60 ^EUR	+0,21 %		-0,79 %	+5,13 %

20/07	Agenda Zonebourse des résultats de sociétés : semaine du 20 au 24 juillet 2026
10/07	Repli des actions européennes cotées aux États-Unis sous forme d'ADR ce vendredi	MT

Communiqués

16/07	Argenx : argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026	PU
16/07	Argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026	GL
23/06	Argenx to Host Autoimmune Myositis R&D Webinar	GL
03/06	Argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren’s Disease at EULAR 2026	GL
28/05	Argenx to Host Myositis R&D Webinar on June 23, 2026	GL
27/05	Argenx to Present at Upcoming Investor Conferences	GL
08/05	Argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG	GL
07/05	Argenx Reports First Quarter 2026 Financial Results and Provides Business Update	GL
07/05	Argenx Reports First Quarter 2026 Financial Results and Provides Business Update	AQ
06/05	Argenx to Present at BofA Securities 2026 Health Care Conference	GL
06/05	Argenx Announces Results of Annual General Meeting and Board of Directors’ Appointment of Karen Massey as Chief Executive Officer	GL
30/04	Argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026	GL
18/04	Argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP	GL
20/03	Argenx announces Annual General Meeting of Shareholders on May 6, 2026	GL
20/03	Argenx : argenx announces Annual General Meeting of Shareholders on May 6, 2026	PU
06/03	Argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline	GL
26/02	Argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update	GL
26/02	Argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update	AQ
26/02	Argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis	GL
23/02	Argenx to Present at TD Cowen 46th Annual Healthcare Conference	GL
19/02	Argenx to Report Full Year 2025 Financial Results and Fourth Quarter Business Update on February 26, 2026	GL
19/02	Argenx to Report Full Year 2025 Financial Results and Fourth Quarter Business Update on February 26, 2026	AQ
13/01	Argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG	GL
13/01	Argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG	AQ
12/01	Argenx Highlights 2026 Strategic Priorities	GL